ArticleLeukemia2026
G3BP2 confers venetoclax resistance by stabilizing ELF1-mediated MCL1 transcription in acute myeloid leukemia.
Article in Leukemia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
Venetoclax is a promising treatment for acute myeloid leukemia (AML) patients, but resistance occurs following the upregulation of MCL1. The RNA-binding protein G3BP2 is upregulated in various solid tumors, and targeting G3BP2 has been shown to restore chemosensitivity. However, the role of G3BP2 in AML development and venetoclax resistance remains unknown. Herein, an integrated analysis revealed that G3BP2 confers venetoclax resistance and correlates with poor outcomes in AML. G3BP2 deficiency inhibits AML proliferation and induces apoptosis in AML cells and xenograft mice. G3BP2 expression aligns with MCL1 levels across AML cohorts, and the regulatory effect of G3BP2 on MCL1 was validated in AML cells. Notably, G3BP2 and MCL1 do not interact directly; instead, G3BP2 interacts with ELF1 mRNA to increase its stability. The transcription factor ELF1 binds to the MCL1 promoter to induce its expression, which can be attenuated by G3BP2 inhibition. Furthermore, C108-mediated inhibition of G3BP2, in combination with venetoclax, has anticancer effects in primary AML cells and in patient-derived xenografts (PDX). C108 increases the therapeutic efficacy of venetoclax and their combination prolongs overall survival (OS) in AML model mice. These findings identify G3BP2 as a regulator of venetoclax resistance through ELF1-mediated MCL1 transcription, suggesting new therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.